Impact Biomedical (IBO) Accounts Payables (2022 - 2026)
Impact Biomedical's (IBO) quarterly Accounts Payables came in at $374000.0 in Q1 2026, down 39.19% YoY from $615000.0 in Q1 2025, and up 7.78% on a QoQ basis from $347000.0 in Q4 2025.
Impact Biomedical (IBO) Accounts Payables (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Accounts Payables data on file, last reported at $374000.0 in Q1 2026.
- Quarterly Accounts Payables fell 39.19% year-over-year to $374000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $374000.0 (down 39.19% YoY) and the FY2025 annual result came in at $347000.0, down 51.33% from the prior year.
- Accounts Payables improved to $374000.0 in Q1 2026, from $347000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1.0 million in Q1 2024 to a low of $301000.0 in Q2 2023.
- A 5-year average of $641307.7 and a median of $576000.0 in 2025 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables surged 227.57% — and 2025, when it tumbled 51.33%.
- Tracing IBO's Accounts Payables over 5 years: stood at $539000.0 in 2022, then surged by 54.36% to $832000.0 in 2023, then retreated by 14.3% to $713000.0 in 2024, then tumbled by 51.33% to $347000.0 in 2025, then gained by 7.78% to $374000.0 in 2026.
- The last three Accounts Payables figures came in at $374000.0 (Q1 2026), $347000.0 (Q4 2025), and $576000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 467,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 467,000.00 |
| Mar 31, 2026 | 374,000.00 |
| Dec 31, 2025 | 347,000.00 |
| Sep 30, 2025 | 576,000.00 |
| Jun 30, 2025 | 554,000.00 |
| Mar 31, 2025 | 615,000.00 |
| Dec 31, 2024 | 713,000.00 |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 986,000.00 |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 832,000.00 |
| Sep 30, 2023 | 476,000.00 |
| Jun 30, 2023 | 301,000.00 |
| Dec 31, 2022 | 539,000.00 |